Pancreatic Adenocarcinoma Clinical Trials in San Antonio, Texas
13 recruitingSan Antonio, Texas
Showing 1–13 of 13 trials
Recruiting
Phase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Immuneering Corporation510 enrolled16 locationsNCT07562152
Recruiting
Phase 1
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Colorectal, CancerMesothelin-Expressing TumorsEpithelial Ovarian Cancer+8 more
Context Therapeutics Inc.70 enrolled9 locationsNCT06756035
Recruiting
Phase 1Phase 2
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Pancreatic AdenocarcinomaGastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.150 enrolled9 locationsNCT07488676
Recruiting
Phase 1
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)+7 more
Revolution Medicines, Inc.574 enrolled5 locationsNCT07349537
Recruiting
Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled159 locationsNCT04389632
Recruiting
Phase 1Phase 2
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Gastric CancerEndometrial CancerHepatocellular Carcinoma+5 more
Seagen, a wholly owned subsidiary of Pfizer714 enrolled61 locationsNCT05208762
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Esophageal CancerPancreatic CancerUrothelial Carcinoma+10 more
Pfizer310 enrolled28 locationsNCT07090499
Recruiting
Phase 1Phase 2
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Advanced Solid TumorsAdvanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaAdvanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer+2 more
Auricula Biosciences Inc.110 enrolled4 locationsNCT07148128
Recruiting
Phase 1Phase 2
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Triple-Negative Breast CancerColorectal, CancerOvarian Cancer+6 more
Apollo Therapeutics Ltd100 enrolled9 locationsNCT06399757
Recruiting
Phase 1
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Advanced Solid TumorNon-small Cell Lung CancerSolid Tumor+3 more
Bristol-Myers Squibb336 enrolled25 locationsNCT05245500
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Bladder CarcinomaEsophageal CarcinomaNon-small Cell Lung Cancer+13 more
Guardant Health, Inc.2,020 enrolled57 locationsNCT05059444
Recruiting
Phase 1Phase 2
Study of LP-184 in Patients With Advanced Solid Tumors
Advanced Solid TumorMetastatic Solid TumorTNBC - Triple-Negative Breast Cancer+4 more
Lantern Pharma Inc.175 enrolled9 locationsNCT05933265